HC Wainwright Issues Pessimistic Forecast for BOLT Earnings

Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) – Analysts at HC Wainwright reduced their FY2024 EPS estimates for Bolt Biotherapeutics in a research note issued to investors on Wednesday, November 13th. HC Wainwright analyst E. White now anticipates that the company will post earnings per share of ($1.57) for the year, down from their previous forecast of ($1.55). HC Wainwright currently has a “Neutral” rating on the stock. The consensus estimate for Bolt Biotherapeutics’ current full-year earnings is ($1.52) per share. HC Wainwright also issued estimates for Bolt Biotherapeutics’ Q4 2024 earnings at ($0.34) EPS, FY2025 earnings at ($0.94) EPS and FY2026 earnings at ($0.74) EPS.

Bolt Biotherapeutics (NASDAQ:BOLT) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.40) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.04). Bolt Biotherapeutics had a negative net margin of 665.56% and a negative return on equity of 69.46%. The company had revenue of $1.14 million for the quarter, compared to the consensus estimate of $1.02 million.

Bolt Biotherapeutics Price Performance

NASDAQ BOLT opened at $0.57 on Friday. The company has a debt-to-equity ratio of 0.21, a current ratio of 3.16 and a quick ratio of 4.28. Bolt Biotherapeutics has a 1-year low of $0.55 and a 1-year high of $1.56. The stock has a market capitalization of $21.64 million, a price-to-earnings ratio of -0.33 and a beta of 0.92. The business’s fifty day moving average price is $0.64 and its 200-day moving average price is $0.73.

Hedge Funds Weigh In On Bolt Biotherapeutics

Several institutional investors have recently made changes to their positions in BOLT. Assenagon Asset Management S.A. purchased a new position in shares of Bolt Biotherapeutics during the 2nd quarter valued at about $26,000. FMR LLC lifted its holdings in Bolt Biotherapeutics by 33.2% during the third quarter. FMR LLC now owns 115,386 shares of the company’s stock valued at $75,000 after purchasing an additional 28,773 shares in the last quarter. Finally, Acuitas Investments LLC lifted its holdings in Bolt Biotherapeutics by 21.7% during the second quarter. Acuitas Investments LLC now owns 630,507 shares of the company’s stock valued at $473,000 after purchasing an additional 112,555 shares in the last quarter. Institutional investors own 86.70% of the company’s stock.

About Bolt Biotherapeutics

Bolt Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company’s lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer.